The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

CRISPR Therapeutics had its first FDA-approved product in December 2023, a treatment for sickle cell disease called Casgevy. It’s also developing treatments for cancer and cardiovascular disease using ...

Learn how CRISPR ETFs provide access to the gene-editing revolution, offering investors a diversified approach without picking individual biotech stocks.

Eli Lilly reported positive Phase 1b data for VERVE-102, a gene-editing cardiovascular therapy, raising fresh competitive ...

Last month, CRSP reported initial top-line results from an early-stage study on CTX310, its investigational in vivo CRISPR-based gene therapy, designed to target ANGPTL3 for the treatment of ...

Imagine being able to edit the genetic code that causes diseases like sickle cell anemia, certain cancers, or inherited blindness. That is not science fiction anymore. It is the working reality of ...

Researchers have been able to manipulate large chunks of genetic code for almost 50 years. But it is only within the past decade that they have been able to do it with exquisite precision – adding, ...

A team in the US has reported promising results after using an improved form of CRISPR to gene-edit human embryos, but a ...